Aptabio Therapeutics Stock Fundamentals
| 293780 Stock | 6,520 210.00 3.12% |
AptaBio Therapeutics fundamentals help investors to digest information that contributes to AptaBio Therapeutics' financial success or failures. It also enables traders to predict the movement of AptaBio Stock. The fundamental analysis module provides a way to measure AptaBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AptaBio Therapeutics stock.
AptaBio |
AptaBio Therapeutics Company Shares Outstanding Analysis
AptaBio Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current AptaBio Therapeutics Shares Outstanding | 10.88 M |
Most of AptaBio Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AptaBio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, AptaBio Therapeutics has 10.88 M of shares currently outstending. This is much higher than that of the sector and significantly higher than that of the Biotechnology & Medical Research industry. The shares outstanding for all Republic of Korea stocks is notably lower than that of the firm.
AptaBio Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AptaBio Therapeutics's current stock value. Our valuation model uses many indicators to compare AptaBio Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AptaBio Therapeutics competition to find correlations between indicators driving AptaBio Therapeutics's intrinsic value. More Info.AptaBio Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value AptaBio Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AptaBio Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.AptaBio Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AptaBio Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AptaBio Therapeutics could also be used in its relative valuation, which is a method of valuing AptaBio Therapeutics by comparing valuation metrics of similar companies.AptaBio Therapeutics is currently under evaluation in shares outstanding category among its peers.
AptaBio Fundamentals
| Return On Equity | -17.47 | |||
| Return On Asset | -0.0568 | |||
| Operating Margin | (17.13) % | |||
| Current Valuation | 794.49 B | |||
| Shares Outstanding | 10.88 M | |||
| Shares Owned By Insiders | 34.04 % | |||
| Shares Owned By Institutions | 3.46 % | |||
| Price To Sales | 926.14 X | |||
| Revenue | 223.68 M | |||
| Gross Profit | 336.97 M | |||
| EBITDA | (6.58 B) | |||
| Net Income | (10.69 B) | |||
| Cash And Equivalents | 6.57 B | |||
| Total Debt | 46.77 M | |||
| Cash Flow From Operations | (8.9 B) | |||
| Beta | 2.39 | |||
| Market Capitalization | 111.21 B | |||
| Total Asset | 64.91 B | |||
| Net Asset | 64.91 B |
About AptaBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AptaBio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AptaBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AptaBio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AptaBio Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AptaBio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AptaBio Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with AptaBio Stock
Moving against AptaBio Stock
The ability to find closely correlated positions to AptaBio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AptaBio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AptaBio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AptaBio Therapeutics to buy it.
The correlation of AptaBio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AptaBio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AptaBio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AptaBio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in AptaBio Stock
AptaBio Therapeutics financial ratios help investors to determine whether AptaBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AptaBio with respect to the benefits of owning AptaBio Therapeutics security.